Latest Breaking News On - Discovery engine - Page 7 : comparemela.com

Arvinas Announces Upcoming Bavdegalutamide Poster

NEW HAVEN, Conn., Oct. 15, 2023 (GLOBE NEWSWIRE) Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs.

Daniel petrylakJeff boyleKirsten owensArvinas incExchange commissionEuropean society for medical oncologyMedical oncologyDiscovery enginePrivate securities litigation reform actArvina annual reportNasdaq arvnRvinas incBreast cancerProstate cancerProtein degradationTargeted protein degradation

Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023

Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Jeff boyleKirsten owensDaniel petrylakArvinas incExchange commissionEuropean society for medical oncologyMedical oncologyDiscovery enginePrivate securities litigation reform actArvina annual report

Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023 - Arvinas (NASDAQ:ARVN), Pfizer (NYSE:PFE)

NEW HAVEN, Conn. and NEW YORK, Oct. 15, 2023 (GLOBE NEWSWIRE) Arvinas, Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE) today announced they will present updated Phase 1/2 data for vepdegestrant (ARV-471) at the 2023

Jeff boyleKirsten owensPfizer incArvinas incEuropean society for medical oncologyArvinas communicationsExchange commissionMedical oncologyDiscovery enginePrivate securities litigation reform actAnnual reportPfizer oncologyBreakthroughs that change patientPfizer newsDisclosure noticeLooking information

Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023

NEW HAVEN, Conn., Oct. 15, 2023 (GLOBE NEWSWIRE) Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it will present updated Phase 1/2 trial data for bavdegalutamide (ARV-110) at the 2023 European Society for Medical Oncology (ESMO) Annual Congress. Bavdegalutamide is an investigational orally bioavailable PROTAC® androgen receptor (AR) degrader and is being developed as a potential treatment

Jeff boyleDaniel petrylakEuropean society for medical oncologyArvinas incExchange commissionMedical oncologyDiscovery enginePrivate securities litigation reform actArvina annual reportAndrogen receptorTargeted protein degradationBiotechnology companyProstate cancer023 european society for medical oncologyCongress website

Arvinas and Pfizer Announce Upcoming Vepdegestrant

NEW HAVEN, Conn. and NEW YORK, Oct. 15, 2023 (GLOBE NEWSWIRE) Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will.

Jeff boyleKirsten owensExchange commissionArvinas incPfizer incArvinas communicationsEuropean society for medical oncologyMedical oncologyDiscovery enginePrivate securities litigation reform actAnnual reportPfizer oncologyBreakthroughs that change patientPfizer newsDisclosure noticeLooking information